News

Novel Antiplatelet Drug Elinogrel Moves Into Phase III Testing

Publish date: September 23, 2010

 

Dr. Rao is a consultant to Novartis, which is developing elinogrel. Dr. Kristensen disclosed that he has received research grants from and serves as a consultant to numerous pharmaceutical companies that have an interest in platelet-inhibiting drugs.

Pages

Recommended Reading

Elevated BNP Predicts Risk in General Population
MDedge Internal Medicine
Serotonin a Possible Marker for Decompensated Heart Failure
MDedge Internal Medicine
FDA Panel Splits on Whether to Take Sibutramine Off the Market
MDedge Internal Medicine
FDA Approves Use of Cardiac Resynchronization Therapy Defibrillators for Heart Failure
MDedge Internal Medicine
FDA Reviewing Actos's Safety
MDedge Internal Medicine
Metabolic Syndrome Threatens Heart Health Regardless of Diabetes Status
MDedge Internal Medicine
FDA Panel Votes to Approve Dabigatran for Reduction of Stroke Risk
MDedge Internal Medicine
Self-Management Techniques Fail to Improve Heart Failure
MDedge Internal Medicine
Type 2 Diabetes Screening Beneficial, Regardless of Treatment Intensity
MDedge Internal Medicine
TAVI Termed the First Choice for Patients Who Cannot Have Surgery
MDedge Internal Medicine